SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for VIVEVE MEDICAL, INC. (VIVE) (CIK 0000879682) — Jul 12, 2021

VIVEVE MEDICAL, INC. (VIVE) (CIK 0000879682)
Date: July 12, 2021 · CIK: 0000879682 · Accession: 0000000000-21-008580

AI Filing Summary & Sentiment

File numbers found in text: 333-257648

Date
July 12, 2021
Author
Not clearly detected
Form
UPLOAD
Company
VIVEVE MEDICAL, INC. (VIVE) (CIK 0000879682)

Letter

United States securities and exchange commission logo July 12, 2021 Scott Durbin Chief Executive Officer Viveve Medical, Inc. 345 Inverness Drive South Building B, Suite 250 Englewood, Colorado 80112 Re:Viveve Medical, Inc. Registration Statement on Form S-3 Filed July 2, 2021 File No. 333-257648 Dear Mr. Durbin: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jane Park at 202-551-7439 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Heidi Mayon, Esq.

Show Raw Text
United States securities and exchange commission logo
July 12, 2021
Scott Durbin
Chief Executive Officer
Viveve Medical, Inc.
345 Inverness Drive South
Building B, Suite 250
Englewood, Colorado 80112
Re:Viveve Medical, Inc.
Registration Statement on Form S-3
Filed July 2, 2021
File No. 333-257648
Dear Mr. Durbin:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jane Park at 202-551-7439 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Heidi Mayon, Esq.